Naresh K N, Advani S, Adde M, Aziz Z, Banavali S, Bhatia K, Belgaumi A, Ezzat A, Khaled H, Mokhtar N, Norton A, Rohatiner A, Sagar T G, Taciyliz N, Temmim L, Venkatesh C, Yan Tang Jin, Magrath I
INCTR at Institut Pasteur, B-1180 Brussels, Belgium.
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):330-7. doi: 10.1016/j.bcmd.2004.08.001.
The International Network of Cancer Treatment and Research (INCTR) recently organized a workshop on non-Hodgkin lymphomas (NHLs) in selected developing countries with the purpose of examining existing information relating to the pathology and management of these neoplasms, and identifying potential areas for research. This report provides a summary of the information presented and is focused primarily on the pathology of NHLs in children and adults. In most countries, the WHO classification of lymphomas was used and most participating centers included immunohistochemistry using a wide array of lymphoid antibodies as part of routine diagnosis. Some of the series had been reviewed by an external panel of experts. B-cell lymphomas accounted for 82-88% of all NHLs. The proportions of chronic lymphatic leukemia (4-6%), mantle cell lymphoma (MCL, 3-5%), and plasmacytoma (2-4%) were similar in the series presented. However, there was a significant variation in the proportion of follicular lymphoma (FL), which accounted for 15% and 11% in India and Kuwait, but less than 5% in Pakistan and Egypt. All of these frequencies are significantly lower than those reported in Western series. Diffuse large B-cell lymphoma accounted for about 35% of cases in India but for more 50% in other countries, but this difference was not accounted for by an increased incidence in a single lymphoma subtype in India, but rather an apparent paucity of several subtypes (such as mantle cell and marginal zone lymphomas (MZL)) in other series. There were relatively high frequencies of Burkitt lymphoma in Egypt (7%) and precursor T-cell lymphoblastic lymphoma in India (6-7%). Peripheral T-cell lymphomas (PTCLs) (not otherwise specified and angioimmunoblastic subtypes) accounted for 3-5% of NHLs, and extranodal lymphoma of T/NK cell type was rare (<1%). These differences in the relative proportions of NHL subtypes among developing countries and between developing countries and the rest of the world presumably arise from differences in environmental and genetic factors that influence lymphomagenesis and strongly suggest that more research in developing countries would provide valuable insights into the pathogenesis of lymphoid neoplasms.
国际癌症治疗与研究网络（INCTR）最近在一些选定的发展中国家组织了一次关于非霍奇金淋巴瘤（NHL）的研讨会，目的是审查与这些肿瘤的病理学和管理相关的现有信息，并确定潜在的研究领域。本报告提供了所呈现信息的摘要，主要聚焦于儿童和成人NHL的病理学。在大多数国家，采用了世界卫生组织的淋巴瘤分类，大多数参与中心将使用多种淋巴样抗体的免疫组织化学作为常规诊断的一部分。部分系列研究已由外部专家小组进行了审查。B细胞淋巴瘤占所有NHL的82 - 88%。在所呈现的系列研究中，慢性淋巴细胞白血病（4 - 6%）、套细胞淋巴瘤（MCL，3 - 5%）和浆细胞瘤（2 - 4%）的比例相似。然而，滤泡性淋巴瘤（FL）的比例存在显著差异，在印度和科威特分别占15%和11%，但在巴基斯坦和埃及低于5%。所有这些频率均显著低于西方系列研究报告的频率。弥漫性大B细胞淋巴瘤在印度约占病例的35%，但在其他国家超过50%，但这种差异并非由于印度单一淋巴瘤亚型发病率增加所致，而是其他系列研究中几种亚型（如套细胞和边缘区淋巴瘤（MZL））明显较少。埃及的伯基特淋巴瘤（7%）和印度的前体T细胞淋巴母细胞淋巴瘤（6 - 7%）的频率相对较高。外周T细胞淋巴瘤（PTCLs）（未另行指定和血管免疫母细胞亚型）占NHL的3 - 5%，T/NK细胞型结外淋巴瘤罕见（<1%）。发展中国家之间以及发展中国家与世界其他地区之间NHL亚型相对比例的这些差异，可能源于影响淋巴瘤发生的环境和遗传因素的差异，这强烈表明在发展中国家开展更多研究将为淋巴样肿瘤的发病机制提供有价值的见解。
